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Our study of themouseAte1 arginyltransferase, a component
of the N-end rule pathway, has shown that Ate1 pre-mRNA is
produced from a bidirectional promoter that also expresses, in
the opposite direction, a previously uncharacterized gene (Hu,
R. G., Brower, C. S.,Wang, H., Davydov, I. V., Sheng, J., Zhou, J.,
Kwon, Y. T., and Varshavsky, A. (2006) J. Biol. Chem. 281,
32559–32573). In this work, we began analyzing this gene,
termed Dfa (divergent from Ate1). Mouse Dfa was found to be
transcribed from both the bidirectional PAte1/Dfa promoter and
other nearby promoters. The resulting transcripts are alterna-
tively spliced, yielding a complex set of Dfa mRNAs that are
present largely, although not exclusively, in the testis. A specific
DfamRNA encodes, via its 3-terminal exon, a 217-residue pro-
tein termed DfaA. Other Dfa mRNAs also contain this exon.
DfaA is sequelogous (similar in sequence) to a region of the
human/mouse HTEX4 protein, whose physiological function is
unknown.We produced an affinity-purified antibody to recom-
binant mouse DfaA that detected a 35-kDa protein in themouse
testis and in several cell lines. Experiments in which RNA inter-
ference was used to down-regulate Dfa indicated that the
35-kDa protein was indeed DfaA. Furthermore, DfaA was pres-
ent in the interchromatin granule clusters andwas also found to
bind to the Ggnbp1 gametogenetin-binding protein-1 and to
the Abt1 activator of basal transcription that interacts with the
TATA-binding protein. Given these results, RNA interference
was used to probe the influence of Dfa levels in luciferase
reporter assays. We found that DfaA acts as a repressor of
TATA-box transcriptional promoters.
This study stems from a serendipitous finding (described
below) in our 2006 investigation of the mouse Arg-tRNA-pro-
tein transferase (R-transferase), encoded by the Ate1 gene. The
Ate1R-transferase is a component of theN-end rule pathway of
protein degradation. In eukaryotes, this pathway is a part of the
ubiquitin-proteasome system. The N-end rule relates the in
vivohalf-life of a protein to the identity of itsN-terminal residue
(1–13). N-terminal degradation signals of the N-end rule path-
way are called N-degrons. The main determinant of an N-de-
gron is a destabilizingN-terminal residue of a substrate protein.
Among such residues, some are primary destabilizing N-termi-
nal residues, which are recognized directly by ubiquitin ligases
of the N-end rule pathway, called N-recognins. Other destabi-
lizing N-terminal residues, called secondary or tertiary destabi-
lizing residues, must be modified through deamidation and/or
arginylation (6, 7, 14) or, alternatively, through N-terminal
acetylation (13) before the corresponding proteins can be tar-
geted by cognate N-recognins. In particular, the destabilizing
activity of N-terminal Asp and Glu requires their conjugation,
by the Ate1 R-transferase (6, 7, 12, 14–16), to Arg, one of the
primary destabilizing residues. In eukaryotes that produce
nitric oxide, R-transferase arginylates not only N-terminal Asp
and Glu but also Cys, after its conversion to Cys-sulfinate or
Cys-sulfonate, in reactions that require nitric oxide and oxygen
(6, 17). Alternative splicing of the mouse Ate1 pre-mRNA pro-
duces at least six isoforms of R-transferase, a metabolically
unstable protein whose enzymatic activity and the in vivo half-
life are down-regulated by heme (7, 12, 14–16).
We found that the transcriptional promoter ofmouseAte1 is
bidirectional, driving the expression of both Ate1 and an oppo-
sitely oriented, previously uncharacterized gene (14), which
was termed Dfa (divergent from Ate1). We wished to explore
Dfa because the proximity and head-to-head arrangement of
Ate1 and Dfa (Fig. 1A) suggested that the corresponding gene
products, R-transferase and Dfa, might be functionally linked,
either directly or through belonging to a specific regulatory
circuit. This work is the beginning ofDfa studies.We show that
Dfa is transcribed from both the bidirectional PAte1/Dfa pro-
moter and other nearby promoters. The resulting transcripts
are alternatively spliced, yielding a complex set of DfamRNAs
that are present largely, although not exclusively, in the testis. A
specific Dfa mRNA encodes, via its 3-terminal exon, a 217-
residue protein, termed DfaA. Other Dfa mRNAs also contain
this exon (Fig. 1, D–F). DfaA is sequelogous (similar in sequence)
(18) to a regionof the previously describedhuman/mouseHTEX4
protein, whose physiological function is unknown. We produced
an affinity-purified antibody to the 26-kDa recombinant mouse
DfaA, whose apparent molecular mass, upon SDS-PAGE, is 35
kDa. This antibody detected a 35-kDa protein in themouse testis,
inmouseNIH-3T3cells, and inhumanHeLaandHEK-293Tcells.
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NIH-3T3 cells indicated that the 35-kDa protein (recognized by
anti-DfaA antibody)was indeedDfaA. This protein is both nuclear
and cytoplasmic. Biochemical fractionations suggested an associ-
ationofDfaAwithmembranes or other rapidly sedimenting struc-
tures. Transient expression of a GFP-DfaA fusion protein indi-
cated that DfaA was present preferentially in the interchromatin
granule clusters (IGCs). In addition, DfaA was found to interact
withspecificproteins, including theAbt1 transcriptional activator.
Given these results, RNAiwasused todown-regulateDfa in assays
with NIH-3T3 cells and a luciferase reporter expressed from a
TATA-boxtranscriptionalpromoter.WefoundthatDfaAactsasa
repressor of this promoter but does not influence the bidirectional
PAte1/Dfa promoter, which contains a CpG island and lacks the
TATA-box. Contrary to our expectation, no functional or mech-
anistic connectionsbetween theDfaprotein(s) and isoformsof the
Ate1 R-transferase were detected so far, apart from the proximity
of their head-to-headoriented genes and the antisense orientation
of some among theDfa andAte1 transcripts (Fig. 1,A andD).
EXPERIMENTAL PROCEDURES
RT-PCR—Total RNA from the brain, kidney, liver, lung,
spleen, and testis (C57 mice) was isolated using the RNeasy kit
(Qiagen, Valencia, CA), according to manufacturer’s instruc-
tions. First-strand cDNA synthesis was carried out using the
Superscript kit and oligo(dT) primer (Invitrogen). These sam-
ples were then used to carry out either standard PCR or
5-RACE, using Invitrogen GeneRacer kit (catalog no. L1500-
01, version J). The following oligonucleotide primers were
employed to detect, by RT-PCR, theDfa cDNA-I (Fig. 1E): for-
ward 5-CGACTGGAGCACGAGGACACTGA-3 (GeneRacer
5 Primer); reverse 5-TTTGCCCAGGCCATTTTCGGC-3
(CA465465-Rev). The primers for the nested reaction were as
follows: forward 5-GGACACTGACATGGACTGAAGG-
AGTA-3 (GeneRacer 5 Nested Primer); reverse 5-CCTGT-
TGGAACTTTTGGACTAACAG-3 (CA465465-Rev2). The
primers that yielded the Dfa cDNA-II were as follows: forward
5-GGACACTGACATGGACTGAAGGAGTA-3 (GeneRacer
5Nested Primer); reverse 5-CCTGTTGGAACTTTTGGAC-
TAACAG-3 (CA465465-Rev2). The primers that yielded the
Dfa cDNA-III were as follows: forward 5-GCCCTTGTATTC-
CACCACCG-3; reverse 5-TTTGCCCAGGCCATTTTC-
GGC-3 (CA465465-Rev). The primers that yielded the Dfa
cDNA-IV were as follows: forward 5-GCCCTTGTATTCCA-
CCACCG-3; reverse 5-TTTGCCCAGGCCATTTTCGGC-3
(CA465465-Rev). The primers that yielded the Dfa cDNA-V
and cDNA-VI were as follows: forward 5-CCTCCTCTGC-
CTGCCAGG-3; reverse 5-TTTGCCCAGGCCATTTTC-
GGC-3 (CA465465-Rev). 3-RACE reactions were performed
using nested PCRs and Invitrogen GeneRacer kit (version J)
according to themanufacturer’s protocol and a forward primer
specific for theDfa exon 7, which is shared byDfa cDNAs char-
acterized so far (Fig. 1E) as follows: 5-CCGAAAATGGCCTG-
GGCAAAGG-3; GeneRacer 3 Primer 5-GCTGTCAACGA-
TACGCTACGTAACG-3, and GeneRacer 3 Nested Primer
5-CGCTACGTAACGGCATGACAGTG-3.
Northern Hybridization—Northern blots of mRNAs from
mouse tissues, containing 2 g of mouse poly(A) RNA per
lane (Clontech), were first probedwith a 180-bpDNA fragment
specific for the Dfa exon 3 (Fig. 1G). This fragment was pro-
duced by PCR from the RT-PCR-derived Dfa cDNA III, using
primers CB120 (5-GATGAAGCTGCTGATGCTGC-3) and
CB121 (5-CTTAGGTTCTCTCACAGAATC-3). After hy-
bridization with the exon 3-specific probe, the membrane was
stripped and rehybridized with a 556-bp DNA probe specific
forDfa exon 7, which is shared byDfa cDNAs characterized so
far (Fig. 1G). This probe was produced by PCR from the RT-
PCR-derived Dfa cDNA III, using primers 5-GAGAGAACC-
TAAGATTGGCCTGGGC-3 and 5-TTTGCCCAGGCCAT-
TTTCGGC-3. Northern DNA probes were 32P-labeled using
the RediprimeII random prime labeling system (Amersham
Biosciences). Hybridizationwith aDNAprobe specific for exon
3 was carried out for 2 h at 68 °C in ExpressHyb solution (Clon-
tech). The blot was then washed once for 30 min at room tem-
perature in 2 SSC, 0.1% SDS, once for 30min at 55 °C in 0.5
SSC, 0.1% SDS, and once for 30 min at 52 °C in 0.1 SSC, 0.1%
SDS, followed by autoradiography. Hybridization with a probe
specific for exon 7 was carried out for 12 h at 65 °C in
ExpressHyb solution. The blot was then washed once for 10
min at room temperature in 2 SSC, 0.1% SDS, once for 30min
at 55 °C in 2 SSC, 0.1% SDS, and once for 30 min at 55 °C in
1 SSC, 0.1% SDS followed by autoradiography.
Antibody to Mouse Dfa—His10-DfaA, an N-terminally His10-
tagged isoform encoded byDfa cDNA I (Fig. 1E), was expressed
in Escherichia coli using the pET-16b vector (Novagen, EMD
Chemicals, Gibbstown, NJ). Briefly, a 1-liter culture of E. coli
BL21(DE3) was grown in LB medium at 37 °C to an A600 of
0.6, then induced with 0.5 mM isopropyl 1-thio--D-galacto-
pyranoside, and incubated for additional 3 h at 37 °C. Cells were
harvested by centrifugation at 2000 g for 10 min at 4 °C. The
cell pellet was resuspended in 50ml of 10mM imidazole, 20mM
Tris-HCl (pH 8.0), 1mg/ml lysozyme, plus EDTA-free protease
inhibitors (Roche Applied Science), followed by a 30-min incu-
bation on ice, and one cycle of freeze-thaw. The resulting sus-
pension was centrifuged at 100,000  g for 35 min at 4 °C.
Inclusion bodies containing His10-DfaA were solubilized by
resuspension in 30 ml of ice-cold 6 M guanidine HCl, 10 mM
imidazole, 0.5 M KCl, 40 mM Tris-HCl (pH 8.0), also containing
0.5 mM phenylmethylsulfonyl fluoride (PMSF). The resulting
solubilized His10-DfaA was clarified by centrifugation at
100,000  g for 35 min at 4 °C and was thereafter purified by
Ni2-agarose affinity chromatography as described previously
(11), except for the presence of 6 M guanidine HCl. Imidazole-
eluted, purified His10-DfaA was dialyzed overnight at 4 °C
against 10% glycerol, 0.15 M KCl, 0.5 mM PMSF, 40 mM HEPES
(pH 7.6) andwas thereafter further purified by SDS-12% PAGE.
0.9 mg of His10-DfaA that was excised from a 12% prepara-
tive-scale polyacrylamide gel was used to inject two rabbits
(six times over the course of 3 months) to produce antisera
(Covance, Berkeley, CA).
Total IgG was isolated by affinity chromatography, using
GammaBind G-Sepharose (GE Healthcare). Pooled IgG frac-
tions were dialyzed against phosphate-buffered saline (PBS:
0.15 M NaCl, 50 mM potassium phosphate (pH 7.5)) containing
10% glycerol and then passed through a column of Affi-Gel-10
(Bio-Rad) with the immobilized (purified) His6-Aat, an unre-
lated E. coli protein described previously (19). The flow-
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through fraction was incubated with Affi-Gel-10 beads conju-
gated to purified mouse His10-DfaA. After 2 h at 4 °C, with
gentle rocking, the sample was loaded into 5-ml disposable col-
umns; the flow-through was collected, and the column was
washed with 20 bed volumes of PBS. Anti-DfaA IgG was eluted
with 0.2 M glycine (pH 2.8) into tubes containing one-third of
elution volume of 1 MK2HPO4 (pH 8.5). The resulting fractions
were pooled, dialyzed against PBS (0.15 M NaCl, 50 mM potas-
sium phosphate (pH 7.5)) containing 10% glycerol, and stored
at20 °C.
Construction of shRNAi Plasmids—Of the four differentDfa-
specific target sequences tested, the most potent microRNA-
like short hairpin (sh) RNA that down-regulatedDfa expression
targeted the sequence GCCACCCTCACTTGAAATCAAA in
exon 7 of Dfa (Figs. 1D and 2A). To construct a corresponding
shRNAi-expressing plasmid, termed pEN-DFAsh4, 0.1 ml of
the DFAsh4 oligonucleotide (5-AGCGACCACCCTCACTT-
GAAATCAAATAGTGAAGCCACAGATGTATTTGATTT-
CAAGTGAGGGTGGC-3), at 50 M, was mixed with 0.1 ml
of 50 M DFAsh4-rev (5-GGCAGCCACCCTCACTTGAAA-
TCAAATACATCTGTGGCTTCACTATTTGATTTCAAG-
TGAGGGTGGT-3) and incubated for at 95 °C for 10 min.
This mixture of single-stranded (unannealed) oligonucleotides
was incubated in a water bath at 70 °C for 10min. The bath was
then turned off, and the temperaturewas allowed to decrease to
room temperature overnight. The resulting double-stranded
oligo was phosphorylated by T4 polynucleotide kinase and
ligated to BfuAI-cut pEN-hU6miR2c (a gift from J. Zavzavad-
jian, California Institute of Technology, Pasadena, CA) (20),
yielding pEN-DFAsh4 (the pEN_hU6miR2c plasmid (20) con-
taining Dfa-sh4). For use in stable transfections, an NheI-di-
gested fragment containing a floxed PGK-hygromycin cassette
(12) was inserted into the single NheI site of pEN-DFAsh4.
Gel Filtration of Dfa from Mouse Testis—Whole-testis
extract was prepared by homogenizing pooled testes of 60
C57BL/6 mice, using a tissue homogenizer (Biospec Products,
Bartlesville, OK) in TMSD Buffer (0.25 M sucrose, 1.5 mM
MgCl2, 0.5 mM dithiothreitol, 10 mM Tris-HCl (pH 7.6)) also
containing 0.5 mM PMSF, added from a freshly prepared stock
solution in isopropyl alcohol. Nuclear (pellet) and cytosolic
(supernatant) fractions were prepared by centrifugation at
800  g for 10 min at 4 °C. The supernatant was frozen with
liquid N2 and stored at 80 °C. The nuclear fraction was
washed three times in TMSD, then resuspended in Nuclear
Buffer (25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 20 mM HEPES (pH 7.9), containing 0.5 mM PMSF), fro-
zen with liquid N2, and stored at 80 °C. In the next step, the
nuclear fraction was thawed on ice and centrifuged at 16,000
g for 90 min at 4 °C, yielding the post-nuclear supernatant. The
cytosolic fraction was thawed and centrifuged at 28,000 g for
90 min at 4 °C, yielding post-lysosomal supernatant. Before gel
filtration, samples of nuclear and cytosolic extracts were dia-
lyzed against Buffer G (10% glycerol, 0.15 M NaCl, 1 mM dithi-
othreitol, 40 mM HEPES (pH 7.9) containing 0.1 mM PMSF)
overnight at 4 °C. The resulting samples were clarified by cen-
trifugation in the SWTi41 rotor (Beckman Instruments, Fuller-
ton, CA) at 28,000 rpm for 2 h at 4 °C. The samples obtained
were concentrated using AmiconUltracentrifugal filter devices
(Millipore, Billerica, MA). The resulting samples (5–20 mg of
total protein in 1.5ml)were subjected to gel filtration, using fast
protein liquid chromatography apparatus and the HiLoad
16/60 Superdex 200 (GE Healthcare) pre-equilibrated with
Buffer G, at 0.5 ml/min. 2-ml fractions were collected and
analyzed, in particular, by immunoblotting with anti-DfaA
antibody.
GFP-Dfa and Immunofluorescence—The plasmid pEGFP-
DfaA was constructed by ligating the DfaA ORF from cDNA I
into KpnI/BamHI-cut pEGFP-C1 (Clontech). Poly-D-lysine (1
mg/ml)-coated coverslips were placed in 35-mm tissue culture
dishes. 1.5 105NIH-3T3 cellswere then seeded overnight and
transfected with the pEGFP-C1 (control) or pEGFP-DfaA plas-
mids. The cells were then grown to70% confluence. For GFP
localization studies, coverslips were fixed in 4% formaldehyde
for 10 min at room temperature, then washed three times in
PBS, and directlymounted usingVectashieldH-1500mounting
medium (Vector Laboratories, Burlingame, CA). For analyses
that also involved immunofluorescence staining, cells were
fixed in 0.2%TritonX-100, 2% formaldehyde, in PBS for 10min
at room temperature followed by acetone at20 °C for 5 min.
After fixation, coverslips were washed three times in PBS,
blocked by incubation with 1% goat serum for 10 min at room
temperature, followed by incubation with an anti-SC35 anti-
body (Abcam, Cambridge, MA) for 2 h at room temperature.
For indirect immunofluorescence, the coverslips were then
washed in PBS at incubated with a Cy3-conjugated goat anti-
mouse IgG (Abcam) for 1 h at room temperature in the dark.
Coverslips were again washed with PBS, mounted using
Vectashield H-1500 mounting medium, and examined by fluo-
rescence microscopy, using Zeiss Axiophot.
Expression of DfaA in Saccharomyces cerevisiae—A colony of
SC295 S. cerevisiae that had been transformed with pCB172
(expressing FLAG-tagged mouse DfaA) was inoculated into 2
liters of the plasmid-retaining SD (Leu) medium, followed by
growth at 30 °C to A600 of 1.0. An equal volume of YPD
medium was then added, and the culture was grown to A600 of
4.0. Cells were harvested by centrifugation, washed once with
cold PBS, and frozen in liquid N2. The frozen pellet (10 g wet
weight) was then ground to a fine powder in liquid N2 using a
mortar and pestle and resuspended (6 ml of buffer per 1 g of
pellet) in yeast Lysis Buffer (10% glycerol 0.05% Nonidet P-40,
0.2 M KCl, 50 mM HEPES (pH 7.5)) containing leupeptin, anti-
pain, pepstatin A, and aprotinin, each at 5 g/ml. The suspen-
sion was centrifuged at 11,200 g for 30min, and the superna-
tant was mixed, with slow rocking, with 1 ml of anti-FLAGM2
affinity gel (Sigma) at 4 °C for 2 h. The affinity beads were col-
lected by a brief spin in a microcentrifuge, then washed once
with 20 bed volumes of yeast Lysis Buffer containing 0.8 M KCl,
twice with 20 bed volumes of yeast Lysis Buffer, then again with
20 bed volumes with Lysis Buffer lacking Nonidet P-40. The
antibody-bound FLAG-DfaA was eluted with yeast Lysis Buffer
lacking Nonidet P-40 and containing FLAG peptide (Sigma) at
0.2 mg/ml.
Yeast two-hybrid assay was carried out using the Match-
maker kit (BD Biosciences). Briefly, S. cerevisiae AH109
(MATa trp1-901 leu2-3, 112 ura3-52 his3-200 gal4 gal80,
LYS2::GAL1UAS-GAL1TATA-HIS3 GAL2UAS-GAL2TATA-ADE2
Dfa Protein
17220 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 22•MAY 28, 2010
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y, on June 11, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
URA3::MEL1UAS-MEL1TATA-lacZ, MEL1) was transformed
with pAS2-DfaA,which expressedGal4DBD-DfaA. The resulting
strain (AH109-Dfa2) wasmated with S. cerevisiaeY187 (MAT
ura3-52 his3-200 ade2-101 trp1-90 leu2-3, 112, gal4 gal80
met URA3::GAL1UAS-GAL1TATA-lacZ MEL1) that had been
pre-transformed with a mouse testis cDNA pACT library
(Clontech). The resulting diploids were incubated on SC plates
containing 5mM 3-aminotriazole (Sigma) and lacking His, Trp,
and Leu. The resulting2.5 106 Trp, Leu, His transfor-
mants were further assayed for their growth on His-lacking,
Ade-lacking media and also for their -galactosidase activity.
Colonies that were Trp, Leu, His, and Ade and exhibited
-galactosidase activity were then grown in Leu-lacking, Trp-
containing media to facilitate the loss of the pAS2-DfaA plas-
mid. pACT plasmids were recovered from the resulting cell
clones, followed by sequencing of cDNA inserts to identify
potential Dfa-binding proteins. Vector “swapping” experi-
ments to verify detected interactions were carried out as fol-
lows. TheDfaAORF was excised from pAS2-DfaA, using diges-
tion with BamHI and SalI. In addition, the Abt1ORF as well as
theGgnBP1ORFwere excised from the corresponding pACT2-
based plasmids, using digestion with BamHI and XhoI. The
excised DfaA ORF was subcloned into pACT2, and the excised
Abt1 ORF and (separately) the GgnBP1 ORF were subcloned
into pAS2, followed by two-hybrid assays with the resulting
plasmids.
Expression of Recombinant Proteins in BL21(DE3) E. coli—
The mouse DfaA cDNA was amplified from pACT-DfaA using
PCR and primers flanked by the BamHI sites. The resulting
DNA fragment was subcloned at position 1 of the BamHI-cut
pET-Duet1 vector (Novagen, EMDChemicals, Gibbstown,NJ),
yielding pCB157. A triple HA-tagged wild-type mouse Ggnbp1
cDNA was amplified from pcDNA3.1-Ggnbp1 using primers
flanked by the NdeI and XhoI sites. The resulting DNA frag-
ment was subcloned at position 2 of the NdeI/XhoI-cut pET-
Duet, yielding pCB182. A third pET-Duet-based plasmid,
pCB183, encoding His6-DfaA at position 1 and Ggnbp1 in posi-
tion 2, was also constructed to coexpress these proteins in
E. coli. 50-ml cultures of E. coli BL21(DE3) were grown at 37 °C
to an A600 of0.6 in LB containing ampicillin (50 g/ml). The
cultures were placed on ice for 15min, followed by the addition
of isopropyl 1-thio--D-galactopyranoside to the final concen-
tration of 0.25 mM and incubation for 4 h at room temperature.
Cells were harvested by centrifugation at 2,000 g for 10min at
4 °C. The pellets were resuspended in 5 ml of 0.15 M NaCl, 10
mM imidazole, 20 mM Tris-HCl (pH 8.0), containing lysozyme
at 1 mg/ml, followed by incubation on ice for 30 min and one
freeze-thaw cycle. The resulting suspensions were centrifuged
at 100,000 g for 30 min at 4 °C. Inclusion bodies were solubi-
lized by resuspension in 5 ml of ice-cold 6 M guanidine hydro-
chloride, 0.5 MKCl, 10mM imidazole, 40mMTris-HCl (pH 8.0),
also containing 0.5 mM phenylmethylsulfonyl fluoride. The
resulting suspensions were clarified by centrifugation at
100,000 g for 30 min at 4 °C. The N-terminally His10-tagged
DfaA was detected in the soluble and insoluble fractions by
SDS-12% PAGE and immunoblotting using anti-DfaA antibody
(see above). The N-terminally HA-tagged GgnBP1 was also
detected by immunoblotting, using amonoclonal anti-HAanti-
body (Sigma).
Expression of Recombinant Proteins inMammalian Cells—A
cDNA encoding the N-terminally triple FLAG-tagged FLAG3-
DfaA (f3DfaA) was amplified using a three-PCR strategy in
which the DfaA moiety was amplified from the pACT-DfaA
plasmid, and a DNA segment encoding an overlapping N-ter-
minal triple-FLAG sequence was amplified by PCR from a sep-
arate plasmid (a gift fromDr. K. Piatkov). The final ORF encod-
ing f3DfaA was amplified using primers flanked by the NheI and
BamHI sites. The resulting DNA fragment was subcloned into
NheI/BamHI-cut pcDNA3.1 (Invitrogen), yielding pCB180.
Mouse NIH-3T3 cells were grown in Dulbecco’s modified
Eagle’s medium (Mediatech, Herndon, VA) containing 10%
fetal bovine serum. Cells were transfected with specific plas-
mids using Lipofectamine-Plus (Invitrogen). After 48 h, cells
were trypsinized, washed in PBS, and lysed by incubation for 10
min on ice, with frequent mixing, in Lysis Buffer (0.5% Triton
X-100, 10% glycerol, 0.5 M NaCl, 1 mM dithiothreitol, 40 mM
HEPES (pH 7.9)) also containing leupeptin, antipain, pepstatin
A, and aprotinin (each at 5g/ml). The extracts was clarified at
10,000 g for 20 min at 4 °C.
Immunoprecipitation and Immunoblotting—These experi-
ments used anti-FLAGM2 beads (Sigma), anti-HAmonoclonal
antibody (12CA5; Roche Applied Science), and the affinity-pu-
rified anti-DfaA antibody (see above). Except for experiments
that employed anti-FLAGM2 beads, immunoprecipitations
were performed by incubating clarified lysates from transfected
NIH-3T3 cells with the desired primary antibodies (at dilutions
indicated under “Results”) for 2 h at 4 °C, with gentle rotation.
Agarose beads with immobilized protein A (Repligen, Wal-
tham,MA) were then added, and the lysates were incubated for
1 more h at 4 °C, with gentle rotation. The beads were then
washed three times in 10% glycerol, 0.15 M NaCl, 1 mM dithio-
threitol, 40 mM HEPES (pH 7.9), followed by elution of the
bound proteins with SDS-sample buffer, SDS-12.5% PAGE, a
transfer of fractionated proteins to Immobilon-P polyvinyli-
dene difluoride membranes (Millipore), and immunoblotting
with antibodies indicated under “Results,” using SuperSignal
West Pico or SuperSignal West Dura chemiluminescent
reagents (Thermo Scientific, Rockford, IL).
Transient Transfection and Luciferase Assay—NIH-3T3 cells
were grown in 5% CO2 at 37 °C in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum and supple-
mented with penicillin/streptomycin/glutamine (Mediat-
ech). The medium was changed every 2–3 days, and cultures
were re-seeded at50% confluency before allowing them to
reach 100% confluency. About 20 h before transfection,
the cultures were seeded at 1.5  105 cells per in 3.5-cm
wells. Cultures at 60–70% confluency were transfected
according to the manufacturer’s protocol, using 0.25 g of
pRL-CMV plasmid (Promega, Madison, WI) expressing
Renilla luciferase from the TATA-box-containing PCMV
promoter, as well as varying amounts of the pCB180 and
pEN-DFAsh4 plasmids (or a plasmid expressing a nonspe-
cific shRNAi), as described under “Results.” Total DNA
among various transfection mixtures was normalized by the
addition of the pcDNA3.1 vector DNA. 5 l of Lipo-
Dfa Protein
MAY 28, 2010•VOLUME 285•NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 17221
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y, on June 11, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
Dfa Protein
17222 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 22•MAY 28, 2010
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y, on June 11, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
fectamine and 5l of Plus reagent (Invitrogen) were used per
well. About 48 h post-transfection, cells in each well were
lysed by incubation in 0.5 ml of Passive Lysis Buffer (Pro-
mega) on an orbital shaker at room temperature for 15 min.
The extracts were clarified by centrifugation at 16,000  g
for 10 min at 4 °C. For luciferase assays, 50 l of extract was
mixed with 0.2 ml of the LARII reagent (Promega), followed
by the addition of 0.2 ml of Stop & Glo reagent (Promega).
The activity of Renilla luciferase was then measured over
10-s intervals using a luminometer.
RESULTS ANDDISCUSSION
Bidirectional PAte1/Dfa Transcriptional Promoter—As de-
scribed in our previous study of the mouse Ate1 R-transferase
(14), the mean GC content of30 kb of the mouse genomic
DNA, from 10 kb upstream to 20 kb downstream of the
Ate1 exon 1B, is40%. In contrast, an800-bp region contain-
ing both exons 1A and 1B of Ate1, from 680 bp upstream of
exon 1B to120 bp downstream of exon 1B, has amean GC
content of 75% (Fig. 1C). Closer inspection identified 85 CpG
dinucleotide repeats in this short region (14). About half of
these CpGs resided in a segment directly upstream of the Ate1
exon 1B that includes the highly conserved 192-bp region 1,
which was demonstrated to function as the core bidirectional
promoter element, located between the alternative Ate1 exons
1A and 1B (Fig. 1,A andD) (14). In particular, we showed, using
in vivo transcription assays, that the above CpG-rich 192-bp
mouse DNA segment (Fig. 1, A and D), which is highly con-
served at least amongmammals, can drive transcription in both
the direction of mapped Ate1 transcripts and in the opposite
direction (14). This evidence prompted our interest in explor-
ing a previously undescribed mouse gene, termedDfa, that was
expressed in the direction opposite that ofAte1 from the above
bidirectional promoter, termed PAte1/Dfa (Fig. 1, A and D) (see
Introduction). To make expression patterns of Dfa easier to
follow, the orientation of theDfa andAte1 transcriptional units
was flipped 180° in Fig. 1 after itsA, in which the orientations of
Dfa and Ate1 are identical to those in previously published dia-
grams (14).
High density of CpG repeats is a characteristic feature of
the previously identified bidirectional promoters in mam-
malian genomes (21–30). Bidirectional promoters are abun-
dant in multicellular eukaryotes;20% of mammalian genes
are located within 1 kb of each other and oriented head-to-
head. In addition, some bidirectionally transcribed chromo-
somal segments appear to be coregulated and functionally
linked (31–35). Bidirectional transcription involves more
than 50% of promoters in the yeast S. cerevisiae (36). In the
parasitic eukaryote Giardia lamblia, most promoters are
bidirectional (37).
Expressed Sequence Tags (ESTs) That Encompass Dfa—Ini-
tially, we carried out BLAST-based analyses of ESTdatabases in
the region of mouse genomic DNA (chromosome 7) directly
upstream of theAte1 gene. Our analyses of several of the result-
ing ESTs (including their additional sequencing, beyond the
regions present in databases) defined four classes of such
sequences. Class 1 included ESTs (AW105867 and BU582987)
that contained genomic sequences in the immediate vicinity of
the PAte1/Dfa promoter spliced to genomic sequences encoding
exon 2 of Ate1. The class 1 ESTs corresponded to mRNAs
encoding isoforms of the Ate1 R-transferase containing exon
1A, specifically Ate11A7A, Ate11A7B, and Ate11A7AB (14). The
ESTs of class 2 included AW414102, BX517440, BG243214,
BY091481, BY241654, and BY267094, whichwere derived from
the immediate vicinity of the PAte1/Dfa promoter but also con-
tained sequences located as far away as 1.6 kb upstream ofAte1.
The ESTs of class 3 (BF434328, AI634505, and AI887824) were
derived from transcripts that were initiated in the immediate
vicinity of PAte1/Dfa, extended in the direction opposite to that
ofAte1, and were clearly spliced, terminating10 kb upstream
ofAte1. The class 4 of ESTs (CA465465 and BM422486) shared
3-exons with ESTs of class 3 but were unlike other ESTs in that
the 5-ends of the corresponding transcripts were 6 kb away
from the bidirectional PAte1/Dfa promoter, in the direction
opposite that of the Ate1 gene (Fig. 1F).
The ESTs derived from transcripts initiated in the immediate
vicinity of the PAte1/Dfa promoter (class 1–3 ESTs) were ob-
FIGURE 1.Genomic characterization of themouseDfa gene. A, bidirectional promoter upstream of themouse Ate1 exon 1B (see Introduction and Refs. 12,
14). Green arrows indicate transcriptional units oriented in both directions from the PAte1/Dfa promoter and also from an unmapped “upstream” promoter that
mediates the expression of Ate1 transcripts containing exon 1A (14). The locations and sizes of some Ate1 exons are shown as well. B, to make expression
patterns ofDfa easier to follow, the orientation of theDfa andAte1 transcriptional unitswas flipped 180° in this andother panels, in comparisonwithA. Percent
identity (from 50 to 100%) of each gap-free segment between14 kb of the mouse and human genomic DNA segments that encompass the Ate1 and Dfa
genes. Position of identities are shown with respect to mouse DNA. Note short regions of significant conservation, including an 200-bp segment that
contains thebidirectionalPAte1/Dfapromoter.C, (GC) content (%)over14kbofgenomicDNA that encompasses the5-regionsofDfaandAte1 reveals aCpG
island at the center of the bidirectional PAte1/Dfa promoter (see themain text). D, shown are the relative positions of Ate1 exons 1A, 1B, and 2, the bidirectional
PAte1/Dfa promoter, and Dfa exons 1–7. The two oppositely oriented arrows at the PAte1/Dfa promoter indicate the directions of Ate1 and Dfa transcription,
respectively. E, different species of RT-PCRDNA fragments that were amplified frommouse testis total RNA in this work and their positions vis a` vis specificDfa
exons that are shown in D. A yellow box exon 7 (Dfa cDNAs I, II, and V) signifies the use of splice junction 1 to produce a Dfa transcript (see panel I). A blue box
exon 7 (Dfa cDNAs III, IV, andVI) signifies the use of splice junction 2 (see panel I) to produce aDfa transcript. F, comparison and classification of ESTs in theNCBI
data base that encompassed the Ate1/Dfa locus. These ESTs are arranged according to their positions vis a` vis specific Ate1 or Dfa exons (see D) and specific
RT-PCR DNA fragments isolated in this study (see E). G, Northern analyses of Dfa expression in mouse tissues. Upper panel, Dfa exon 3-specific probe. Middle
panel, Dfa exon 7-specific probe. Lower panel, -actin mRNA probe was used to verify the uniformity of total RNA inputs. H, RT-PCR DNA fragments amplified
from total RNA isolated from indicated mouse tissues. Upper panel,0.7-kb Dfa-specific RT-PCR DNA fragment amplified from testis RNA using forward and
reverse primers annealing to the class IV EST-CA465465 (see F) (forward 5-CCAGACCACAGAGCCAGCAC-3; reverse 5-TTTGCCCAGGCCATTTTCGGC-3). DNA
sequence analyses of RT-PCR-amplifiedDNA fragments from tissues other than the testis indicated that theywerenonspecific (unrelated to theDfa/Ate1 locus)
(data not shown). Middle panel,1.7 and0.8 kb Dfa-specific RT-PCR DNA fragments amplified from testis RNA using a forward primer annealing genomic
DNA in the vicinity of the bidirectional PAte1/Dfa promoter (5-GCCCTTGTATTCCACCACCG-3) and a reverse primer annealing to the class IV EST-CA465465
(reverse 5-TTTGCCCAGGCCATTTTCGGC-3). Bottom panel, -actin-specific RT-PCR DNA fragments derived from all tissues (mix, equimolar mixture of cDNA
isolated frombrain, kidney, liver, lung, spleen, and testis;RT, indicates the presence or absence of reverse transcriptase used in generating 1st strand cDNA).
I, diagram of the Dfa pre-mRNA splicing that involved depicting the alternative splice site selection between Dfa exons 6 and 7. See E and the main text for
additional details.
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tained from various cellular sources, including tumor cells. In
contrast, all ESTs that corresponded to transcripts initiated
(in the direction opposite the orientation of Ate1) between 6
and 10 kb away from PAte1/Dfa (class 4 ESTs) were detected only
in the testis. At the time of our initial analyses of themouseDfa
gene, GenBankTM contained an entry for a putative locus,
XM_146107 (now calledDfa), that had been predicted by auto-
mated analysis of the annotated mouse genomic sequence
(NT_081265), using the GNOMON gene prediction method
(www.ncbi.nlm.nih.gov). That entry assisted our analyses and
assembly of the intron/exon structure of the Dfa gene, as most
of the exons proposed by XM_146107 were similar to those in
relevant ESTs derived from databases and from our own RT-
PCR analyses as well (Fig. 1, E and H). A more recent Gen-
BankTM accession number XM_001479657 encodes a hypo-
thetical mouse protein (LOC100043163) whose sequence is
identical to the sequence encoded by the exons 5 and 6 of the
Dfa cDNA II (Fig. 1, D and E). In addition, the GenBankTM
accession number XM_001479095 encodes a hypothetical
mouse protein (LOC100047902) whose sequence is identical to
the sequence encoded by the exon 7 of Dfa (Fig. 1, D and E).
Class 3 ESTs (Fig. 1F) suggested that transcripts specified by
genomic sequences in the vicinity of the PAte1/Dfa promoter
could be spliced to regions between 6 and 10 kb from PAte1/Dfa,
in the direction opposite the orientation of Ate1. To verify this,
we isolated total RNA from C57BL6mouse brain, kidney, liver,
lung, spleen, and testis, followed by RT-PCR analyses (Fig. 1H).
Forward primers used in these reactions were specific for
genomic DNA in the vicinity of the PAte1/Dfa promoter,
although reverse primers were specific for the sequence of a
class 4 EST called EST-CA465465 (GenBankTM). No specific
RT-PCR products were amplified using these primers (as well
as additional forward primers) from the mouse brain, kidney,
liver, lung, or spleen RNA, whereas at least six different Dfa
cDNAs were amplified from the testis RNA (Fig. 1, E and H).
Dfa cDNAs III–VI, the three largest cDNAs that had been
isolated by RT-PCR, correspond to class 3 ESTs in that the
transcripts that gave rise to those cDNAs were initiated in the
vicinity of the bidirectional PAte1/Dfa promoter, were extended
in the direction opposite that of the Ate1 gene, and contained
exons encoded by genomic DNA between4 and10 kb away
from PAte1/Dfa. The 5-rapid amplification of cDNA ends (5-
RACE) technique (38) revealed that a transcript that corre-
sponded to theDfa cDNA III was initiated just 161 nucleotides
from the exon 1B of Ate1, between exons 1A and 1B. Specifi-
cally, the Dfa cDNAs III and IV were antisense to Ate1-encod-
ing transcripts that contained the exon 1A of Ate1, its most
upstream alternative exon (Fig. 1E). These Dfa transcripts
extended for up to 1.2 kb before splicing to the Dfa
(XM_146107) exons 3, 6, and 7. The Dfa cDNAs V and VI are
derived from transcripts that were spliced to Dfa exon 3 at a
location 805 nucleotides upstream of the splice site that pro-
duced the Dfa cDNA III (Fig. 1E).
In addition toDfa transcripts initiated at or close to the bidi-
rectional PAte1/Dfa promoter, we also isolated two RT-PCR
products,Dfa cDNAs I and II, that were similar to class 4 ESTs
in that the corresponding transcripts were initiated between 5
and 6 kb away from PAte1/Dfa, in the direction opposite that of
theAte1 gene (Fig. 1H). TheDfa cDNA II encompasses the class
3 EST-CA465465 (as well as the putative genomic locus XM_
001479657 and XM_001479095) and contains the exons 5–7
that are present in XM_146107 (Fig. 1E). 5-RACE analysis
of theDfa cDNA II mapped its 5-end to a region5.8 kb away
of the bidirectional PAte1/Dfa promoter. Dfa cDNA I is distinct
in that it contains an alternative, much smaller 5-exon (exon
4), located1 kb upstream of genomic DNA that contains the
5-exon specific for Dfa cDNA II (Fig. 1E). As described above,
the 5-ends of the Dfa cDNAs I and II are located 5 kb away
from the 5-ends of class 1–3 Dfa ESTs (Fig. 1, E and F). Thus,
transcripts that give rise to the Dfa cDNAs I and II and to
cDNAs represented by class 4 ESTs are expressed, most likely,
not from the bidirectional PAte1/Dfa promoter but from other
currently unknown promoters. In addition to the above Dfa
isoforms, we have also isolated (but not yet further character-
ized) an RT-PCR cDNA from testis that contains the putative
exon 2 of XM_146107 (data not shown).
Together, specific cDNA clones from EST databases and our
own RT-PCR results (Fig. 1) confirmed the existence of theDfa
gene and its head-to-head arrangement vis a` vis Ate1 (Fig. 1, A
and D). These results revealed a complex set of Dfa-encoded
mRNAs that are produced by alternative splicing (39) of pri-
mary Dfa transcripts that are expressed from several promot-
ers, including PAte1/Dfa (Fig. 1, D–F).
To explore evolutionarily conserved Dfa-relevant genomic
segments that contain transcriptional promoters, other regula-
tory elements, or exons that might have been overlooked by
RT-PCR analyses, we produced a percent identity plot (40, 41)
of gap-free segments that are conserved between14 kb of the
mouse genomic DNA in the vicinity of the bidirectional
PAte1/Dfa promoter on the mouse chromosome 7F3 and the
corresponding human genomic sequence on chromosome
10q26.13. This analysis (Fig. 1B) showed that, similarly to the
Ate1 exons 1A, 1B, and 2 and the bidirectional PAte1/Dfa pro-
moter, the genomic sequences of specific mouseDfa exons that
had been identified by RT-PCR contained more gap-free DNA
segments with greater than 50% identity to the corresponding
human genomic DNA than nearby less sequelogous (less simi-
lar in sequence) (18) DNA regions. A low DNA sequelogy
between mouse and human DNA in the region from1 to4
kb relative to the PAte1/Dfa promoter (within Dfa) strongly sug-
gests the absence of additional Dfa exons or regulatory ele-
ments in this region.
At the same time, our percent identity plot analyses revealed
a high density of nearly identical, gap-free mouse-versus-hu-
man DNA segments between the Dfa exons 3 and 5 (Fig. 1B),
indicating that most of this genomic region was under a drift-
reducing selection after the divergence of rodent and monkey
lineages. Transcripts that give rise to theDfa cDNAs I and II, as
well as to class 4 Dfa ESTs, have been found to initiate in this
region (see above), strongly suggesting that the evolutionary
stability of specific nucleotide sequences in this area stems, at
least in part, from the likely presence of additional Dfa tran-
scriptional promoters (other than PAte1/Dfa). We did not
include this genomic segment in our reporter assays (see
below), but an examination of genomic DNA in the interval of
4–6 kb from thePAte1/Dfapromoter (in the direction opposite
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to that of Ate1) by PromoterInspector (Genomatix) (42) did
suggest the presence of a putative promoter in that region (data
not shown).
Our Northern analyses in the earlier study of mouse Ate1
(14) used a DNA probe in the vicinity of the PAte1/Dfa promoter
(upstream of the Ate1 exon 1B) that detected transcripts from
the DNA strand complementary to the Ate1-specific strand.
Those preliminary investigations of what we now call Dfa
revealedmRNA species of 1.5–1.7 kb in the heart, brain, spleen,
lung, liver, and kidneywith amuch higher level of thismRNA in
the testis where additional, less intenseDfa-specific RNAbands
were present as well, at4.5,3,2.3, and	1.35 kb (see Fig.
5C in Ref. 14). In this work, we carried out Northern analyses
with total RNA from various mouse tissues using a Dfa exon
3-specific 181-bp DNA probe, and also an exon 7-specific
556-bp probe. The exon 3-specific probe detected a single
1.7-kb RNA in the liver, as well as a major 1.5-kb and a
minor 2.5-kb RNA in the testis (Fig. 1G). Stripping and rep-
robing the same Northern blot with aDfa exon 7-specific DNA
probe revealed amajor1.5-kbRNA in the testis, in addition to
a fewminor RNAs close to1.5 kb (Fig. 1G). Given a relatively
low sensitivity of the second (reprobed) Northern blot and the
much higher expression ofDfa in the testis, in comparisonwith
other tissues, these results are consistent with the previously
observed presence of low abundance, Dfa-specific mRNAs in
tissues other than testis (see Fig. 5C in Ref. 14).
Sequelogs ofMouse Dfa—To address the presence of proteins
similar to Dfa, in the mouse or other species, we focused on the
ORF encoded entirely by theDfa exon 7 that is present in all of
examined Dfa-specific RT-PCR products. With the exception
of the 5-exon of theDfa cDNA III, the 3-terminal exon 7 is the
largest Dfa exon (Fig. 1, D and E). This ORF encodes a 217-
residue protein, termedDfaA, with a calculatedmolecular mass
of 26 kDa and a deduced pI of 9.84 (Fig. 2A). BlastP analyses
showed that this amino acid sequence exhibits 37% identity and
52% sequelogy (sequence similarity) (18) to human HTEX4, a
protein of unknown function encoded by the major histocom-
patibility complex class I gene cluster on human chromosome 6
(Fig. 2B) (43, 44). In addition, the amino acid sequence encoded
by themouseDfa exons 5 and 6 inDfa cDNA II (upstreamof the
exon 7-encoded 217-residue sequence) is 48% identical and
73% sequelogous to human HTEX4, indicating that the seque-
logy of HTEX4 and Dfa involves more than exon 7 of Dfa (Fig.
2B). Similarly to mouse Dfa, the human HTEX4 pre-mRNA
(and presumably its mouse counterpart as well) undergoes
extensive alternative splicing in the testis (44).
Analyses by tBLASTn that employed the 217-residue C-ter-
minal region of DfaA as a query (see Fig. 2A) identified two
HTEX4-like genes on mouse chromosome 17 that encoded
proteins (of unknown function) that are sequelogous to mouse
DfaA. In addition, although no sequelogs of Dfa were found
to be encoded by yeast, nematode, fly, or fish genomes, all
examined mammalian genomes contained HTEX4-like genes,
including putative Dfa genes (data not shown). Moreover,
sequence alignments also showed that thoseHTEX4-like genes,
in different vertebrates, that mapped close to the correspond-
ingATE1 genes (encoding R-transferase) (Fig. 1,A andD) were
more sequelogous to mouse Dfa than to other HTEX4-like
genes of the same species (data not shown). Thus,Dfa is amem-
ber of a distinct gene family at least in mammals.
Close examination of Dfa-specific genomic DNA sequences
shows that a splice site selection between the common Dfa
exons 6 and 7 (Fig. 1I) determines whether or not the DfaAORF
can be extended in the 5 direction. Although theAG-GT splice
junction-2 was found between exons 6 and 7 in Dfa cDNAs III,
IV, and VI, an AG-TG splice junction-1 was found between
these exons inDfa cDNAs I, II, andV (Fig. 1,E and I). In the case
of Dfa cDNA II, the selection of splice junction-1 makes possi-
ble a contiguous ORF formed by the exons 5–7 inDfa cDNA II.
This putative ORF encodes a 361-residue protein, termedDfaB.
Its calculated molecular mass is 42 kDa, and its deduced pI is
9.65. DfaA and DfaB share the 217-residue C-terminal region
(encoded by exon 7) and differ by the presence of the 144-
residue N-terminal extension in DfaA (encoded by exons 5 and
6 of cDNA II) (Fig. 2A). Although a more detailed study of Dfa
isoformswill be required for their comprehensive characteriza-
tion, our results strongly suggest that most, if not all, Dfa iso-
forms share the 217-residue C-terminal sequence, encoded by
exon 7.
Expression, Intracellular Localization, and Possible Com-
plexes Containing Dfa—To detect endogenous Dfa, we pro-
duced an affinity-purified polyclonal rabbit antibody, termed
anti-Dfaex7, to the E. coli-expressed 217-residue mouse DfaA,
which is encoded by the Dfa exon 7 (Fig. 1, D and E). (As men-
tioned above, the 26-kDa recombinant DfaA migrated, upon
SDS-PAGE, as an35-kDa protein.) Immunoblotting analyses
with this antibody, affinity-purified against immobilized DfaA
(see “Experimental Procedures”), detected a putative42-kDa
Dfa protein that was present in whole-cell extracts from the
mouse testis, hippocampus, cerebellum, total brain, heart,
spleen, liver, and kidney (Fig. 3A). Additional, tissue-specific
putative Dfa species were also observed in most of the tissues
examined. For example, a putative 47-kDa Dfa protein was
present in heart extracts, and a putative38-kDaDfa was pres-
ent in the hippocampus and the liver (Fig. 3A). Testis extracts
contained, in addition to the putative42-kDaDfa isoformand
FIGURE 2. Amino acid sequence of Dfa. A, deduced mouse Dfa amino acid sequence encoded by Dfa cDNA-II (see Fig. 1E). This sequence includes the
217-residue sequence (in black letters) that is encoded by exon 7 and includes the DfaA isoform (see the main text). DfaB, a larger isoform shown here, differs
from DfaA in containing an N-terminal extension (in red letters) that is encoded by exons 5 and 6 and is produced by selection of the splice junction 1 in Dfa
cDNA-II (Fig. 1, E and I). Exon junctions, including alternative junctions at nucleotide positions 661 and 668, are indicated by vertical bars. The corre-
sponding Dfa exons (see Fig. 1, D and E) are indicated on the right. The deduced N-terminal Met residue of the DfaA isoform is circled. Dfa-coding
sequences that were targeted by RNAi (shRNA) in the present study are boxed and are denoted on the left. Underlined nucleotides denote the deduced
poly(A) signal. Nucleotide 1 is the 5-end of Dfa cDNA-II mapped by RACE (see under “Experimental Procedures”). B, ClustalW2-based amino acid
sequence alignments of mouse and rat Dfa versus human and mouse Htex4 (see the main text). Note that the sequences encoded by Dfa exons 6 and
7 are sequelogous (18) to Htex4. Residues of similar physicochemical properties are similarly colored. Specifically, A, V, F, P, M, I, L, and W are shown in
red; D and E are shown in blue; R, H, and K are shown inmagenta, and S, T, Y, H, C, N, G, and Q are shown in green. *, identical residues in all of the aligned
sequences; :, highly conserved; ., weakly conserved.
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several otherminor bands, amajor putativeDfa of35 kDa (i.e.
of the same apparent molecular mass as the recombinant DfaA
protein) (Fig. 3A). An apparently identical Dfa isoformwas also
detected in extracts from mouse NIH-3T3 cells, as well as
human HeLa and 293T cells (Fig. 3B).
These findings suggest that different cell types, if they pro-
duce Dfa at all, tend to produce different isoforms of Dfa. The
35-kDa protein, a major species in the testis and in NIH-3T3
cells, is actually Dfa, because it can be specifically down-regu-
lated, in 3T3 cells, using RNAi specific forDfa (see below). The
Dfa Protein
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other less abundant Dfa species, for example the ones detected
in heart and liver extracts (Fig. 3A), will remain tentative until
Dfa/ (Dfa-lacking) mouse mutants are constructed and
employed as null-Dfa controls for antibody specificity. Under
the immunoblotting conditions used, the anti-Dfaex7 antibody
could detect 0.1 ng of recombinant DfaA (data not shown)
and could also detect the band of endogenous DfaA in400 ng
of total protein extracted frommouse 3T3 cells (Fig. 3C). Thus,
DfaA comprised0.025% of soluble proteins in these cells, i.e.
8 104 DfaA molecules per cell.
To address the intracellular distribution of Dfa, we used
immunoblotting with the affinity-purified anti-Dfaex7 antibody
to analyze fractions of extract from mouse testis (Fig. 3D). A
previously characterized, affinity-purified antibody to the
mouseAte1R-transferase (Fig. 1A) (6, 7, 14)was also employed,
in parallel, to compare the levels of Ate1 in the same fractions.
(Ate1 and Dfa are expressed from the bidirectional PAte1/Dfa
promoter (Fig. 1,A andD).)We found that the bulk of Ate1 was
present in the cytosol fraction of extracts from the testis (Fig.
3D). In contrast, the endogenous 35-kDa DfaA (the only Dfa
isoform for which the specificity of anti-Dfaex7 antibody was
confirmedusingRNAi (see below)), was present in both nuclear
and cytoplasmic fractions. Moreover, the bulk, although not all
of DfaA, could be pelleted by centrifugation of cytoplasmic and
nuclear fractions of a detergent-free testis extract for 90 min at
28,000 and 16,000  g, respectively (Fig. 3D), suggesting an
association of DfaA with membranes and/or cytoskeleton.
We also askedwhetherDfaAwas present in the testis as a part
of an endogenous complex stable enough to be detected by gel
filtration of testis extracts, using immunoblotting of fractions
with anti-Dfaex7 antibody. Purified recombinant mouse DfaA
(expressed in S. cerevisiae; see under “Experimental Proce-
dures”) eluted from a Superdex-200 column in a single peak
centered at fraction 21 (Fig. 3E, bottompanels) and correspond-
ing to the molecular mass of 30–50 kDa for a globular protein,
in agreement with the apparent molecular mass of monomeric
DfaA fractionated by SDS-PAGE (the actual molecular mass of
the recombinant DfaA was 26 kDa; see above). A small propor-
tion of DfaA in either the cytosolic or nuclear testis extract also
eluted at the position of monomer, but the bulk of DfaA
migrated in the region corresponding to the molecular mass of
100–150 kDa (Fig. 3E, upper and middle panels). The compo-
sition and function of this endogenous DfaA complex(es)
remain to be determined.
In addition, we transiently expressed, in mouse NIH-3T3
cells, an EGFP-DfaA fusion. Although the EGFP protein lacks
known nuclear localization signals, EGFP (or GFP) alone is
known to be present, in diffuse patterns, in both the cytoplasm
and the nucleus, because, at least in part, of the low size of EGFP
(27 kDa) that allows its nuclear localization signal-independent
transport to the nucleus (Fig. 3F) (45). Despite this drawback of
EGFP as a location marker, the results with EGFP-DfaA were
meaningfully interpretable, because in 95% of EGFP-DfaA-
expressing cells the bulk of this fusion was predominantly
nuclear, in contrast to EGFP alone (Fig. 3, H and cf. F). A pre-
dominantly nuclear localization of DfaA was consistent with it
containing the sequence KKKPK, a putative nuclear localiza-
tion signal (Fig. 2A). Moreover, in contrast to EGFP alone, the
nuclear EGFP-DfaA protein often exhibited a speckled pattern
(Fig. 3, H and L) that under higher magnification appeared as
cavity-containing structures (Fig. 3Q). In a minority (5%) of
cells that expressed EGFP-DfaA, it was associated, in particular,
with plasmamembrane regions (Fig. 3J), in agreementwith bio-
chemical fractionation data that suggested an association of
DfaA with rapidly sedimenting structures (Fig. 3D).
IGCs are interconnected, dynamic nuclear structures that
are enriched in pre-mRNA splicing factors, including the non-
small nuclear ribonucleoprotein splicing factor SC-35, which is
commonly employed as an IGCmarker (46). During transcrip-
tional repression, IGCs undergo an actin-dependent reorgani-
zation from diffuse interconnected speckles to larger, con-
densed (and apparently unconnected) speckles associated with
RNA polymerase II (47, 48). When stained for SC-35, IGCs
from transcriptionally inactive cells contain a cavity that se-
questers, in particular, the hyperphosphorylated large subunit
of RNA polymerase II (49). At higher magnifications, most of
DfaA-containing nuclear speckles, observed in the bulk of cells
that expressed EGFP-DfaA, were large, condensed, and con-
tained characteristic cavities (Fig. 3Q). Confirming their iden-
tity as IGCs, we found that the IGC marker SC-35 colocalized
with EGFP-DfaA-containing nuclear speckles (Fig. 3, L–Q).
Interestingly, although IGCs (stained with anti-SC-35 anti-
body) were small and scattered throughout the nucleus in non-
transfected cells (Fig. 3O), the IGCs in cells that expressed
FIGURE3.CharacterizationofmouseDfa.A, endogenousDfadetectedby SDS-PAGEand immunoblotting (IB), with affinity-purified anti-Dfaex7 antibody (see
“Experimental Procedures”) of extracts frommouse testis, hippocampus (hc), cerebellum (cb), total brain (brain), heart, spleen, liver, and kidney. Lower panel,
immunoblotting of the same extracts using an anti-tubulin antibody. Arrow on the left indicates a major 35-kDa Dfa species in the testis. B, endogenous
35-kDaDfa detected using anti-Dfaex7 and immunoblotting of extracts frommouseNIH-3T3 cells and humanHeLa andHEK-293T cells.C, 35-kDaDfa, detected
by immunoblottingwith anti-Dfaex7, in serially diluted extracts fromNIH-3T3 cells. Lanes 1–3, 20, 4, and 0.4g of total protein, respectively.D, relative levels of
the 35-kDa Dfa (detected with anti-Dfaex7, upper panel) and Ate1 (detected with anti-Ate1; lower panel) in specific fractions of a mouse testis extract. WCE,
whole-cell extract; cyto, cytosolic fraction; post-lys super, post-lysosomal supernatant (28,000  g for 90 min); post-nuclear super, post-nuclear supernatant
(16,000  g for 90 min). E, immunoblotting, using anti-Dfaex7, of fractions collected from a Superdex-200 column fractions 4–30. Upper panel, cytosolic
subfractionofmouse testis extract.Middle panel, samebut a nuclear extract. Lower panel,gel filtrationpattern, on the same column, of the recombinantmouse
DfaA that hadbeenpurified from S. cerevisiae (see “Experimental Procedures”). F–K, Subcellular localization of eGFP-DfaA transiently expressed inNIH-3T3 cells.
F and G, fluorescent and phase contrast images, respectively, of cells that had been transiently transfected with the control plasmid pEGFP-C1, expressing
eGFP.H and I, same but cells were transfectedwith pEGFP-DfaA, which expressed eGFP-DfaA. Note the predominantly nuclear localization of eGFP-DfaA. J and
K, same but with cells (also transfected with pEGFP-DfaA) in which eGFP-DfaA was apparently associated plasma membranes (	10% of transfected cells).
L–P, subnuclear localization of eGFP-DfaA transiently expressed in NIH-3T3 cells. L, fluorescent image showing large and “condensed” nuclear speckles in cells
expressing eGFP-DfaA (white arrow).M, 4,6-diamidino-2-phenylindole stainingof the same field as in L reveals four additional non-transfected cells.N, merged
image of L and M (4,6-diamidino-2-phenylindole and EGFP). O, immunofluorescent image, produced using an anti-SC35 antibody (see the main text) and
showing condensed nuclear speckles in the nucleus of a cell that expressed eGFP-DfaA (see L). P, merged image of L andO, suggesting colocalization of SC-35
and eGFP-DfaA in the nuclear IGC (see the main text). Q, higher magnification of three large, condensed EGFP-DfaA-containing nuclear speckles, one of them
with visible “cavities,” in a single nucleus (see also the main text). Bars in F, L, and Q indicate 10 m.
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EGFP-DfaA (cellsmarkedwithwhite arrows in Fig. 3, L–P) were
larger and more condensed. Thus expression of EGFP-DfaA
induces IGC reorganization to an architecture characteristic of
transcriptionally repressed cells (Fig. 3O).
Dfa-Specific RNAi Confirms the Identity of a Putative Dfa
Isoform Detected by Anti-Dfaex7 Antibody—To down-regulate
the expression of Dfa in cultured cells and to verify specificity
of the anti-Dfaex7 antibody, we
employed microRNA-like shRNAs
(DFAsh1, DFAsh2, DFAsh4, and
DFAsh5) specific to four different
regions mRNA encoding Dfa (Fig.
2A), using transient coexpression of
these shRNAs with DfaA or DfaB in
NIH-3T3 cells. Because theDFAsh1
sequence is complementary to a
sequence in exon 6 (Fig. 2A), the
ability of DFAsh1 to inhibit the
expression of a transfected Dfa
cDNAwas confined to the DfaB iso-
form (Fig. 4, A and B) whose cDNA
contains exons 5–7 (Figs. 1E and
2A). Whereas DFAsh2 was rela-
tively ineffective at reducing the
expression of transiently trans-
fected DfaA or DfaB cDNAs (Fig. 4,
A and B), DFAsh4 and DFAsh5
reduced the expression of both Dfa
isoforms to undetectable and barely
detectable levels, respectively (Fig.
4, A and B). To determine the rela-
tive efficacies of DFAsh4 and
DFAsh5, we examined the effects of
varying their levels on expression of
the transiently cotransfected DfaA
cDNA. Although the expression of
DfaA was inversely proportional to
input amounts of the DFAsh5-ex-
pressing plasmid in a cotransfection
mixture (Fig. 4C), even the lowest
examined levels of the DFAsh4-ex-
pressing plasmid reduced DfaA
expression to levels undetectable by
immunoblotting (Fig. 4D).
To determine whether the ex-
pression of endogenous DfaA could
be strongly inhibited with DFAsh4,
we isolated individual NIH-3T3 col-
onies stably transfected with the
constitutively active pEN-DFAsh4
(Fig. 4E). Immunoblotting of whole-
cell extracts using the anti-Dfaex7
antibody showed that expression of
the endogenous 35-kDa DfaA was
reduced by up 87% in different
clonally derived DFAsh4-express-
ing 3T3 cell cultures (Fig. 4E and
data not shown). In addition to
establishing a method for knocking down the expression of
endogenous DfaA in a cell line, these experiments validated the
specificity of our anti-Dfaex7 antibody. Interestingly, while iso-
lating and propagating the above cell clones, we noticed fewer
viable pEN-DFAsh4-containing 3T3 cell colonies than those
containing the control (non-Dfa-specific) pEN-shGFP plasmid,
under conditions where similar initial amounts of cells were
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FIGURE 4. RNAi of Dfa. A, relative efficacies of different shRNAs in down-regulating the expression of exoge-
nous (triple-FLAG-tagged) f3DfaA in NIH-3T3 cells, measured using immunoblotting with anti-FLAG antibody.
Lane1, pEN, theparental pEN_hU6miR2cvector for shRNAs. Lane2, shRNAspecific forphospholipaseC (PLC).
Lanes 3–6, DFAsh1, DFAsh2, DFAsh4, andDFAsh5, specific for different regions ofDfamRNAs (see Fig. 2A). Lane
7, control 3T3 cells, mock-transfected. B, same as in A but with f3DfaB. Equal numbers of cells were transfected
with equal amounts of a Dfa-expressing plasmid, an shRNA-expressing plasmid, or control vectors. C, effect of
increasing amounts of transfectedDFAsh5 on the levels of exogenous f3DfaA. Lane 1, transfected with a vector
alone. Lane 2, transfected with 1 g of pcDNA-FLAG-DfaA (pCB180), expressing f3DfaA. Lane 3, same as lane 2
but cellswere also cotransfectedalsowith1gofpEN-DFAsh5, expressingDFAsh5 shRNA. Lane4, sameas lane
3 but 2 g of pEN-DFAsh5. Total amounts of DNA in each transfection were equalized using an empty DNA
vector.D, same as inCbutwithDFAsh4 shRNA.Asterisks inA–Ddenote a protein cross-reactingwith anti-FLAG
antibody. E, comparing, using anti-Dfaex7 immunoblots, the levels of endogenous DfaA in independently pro-
ducedNIH-3T3 cell clones, either a control cell line or stably transfectedwith pEN-DFAsh4DfaA (two represent-
ative examples, out of a number of cell clones thus produced, are shown). Upper panel, quantitation of the
levels of endogenous DfaA that was detected by immunoblotting with anti-DfaA (middle panel). Lower panel,
relative levels of the Ate1 R-transferase in the same cell clones, determined by immunoblottingwith anti-Ate1
antibody. Lane 1, NIH-3T3 cells stably transfected with a vector alone. Lanes 2 and 3, same but with a plasmid
expressing DFAsh4 shRNA (30 and 13% of control DfaA levels, respectively, in different 3T3 clones).
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plated (data not shown). In addition, individual colonies con-
taining DFAsh4 grew at slightly but significantly lower rates
than those expressing GFP-specific shRNAi (1.1 doublings/
day  0.012; n 
 35 versus 1.3 doublings/day  0.019; n 
 5,
respectively (p	 0.03)). We also noticed that the early growth
of DFAsh4-expressing cell colonies was particularly delayed, in
comparison with colonies expressing GFP-specific shRNAi.
Together, these findings validated the use of anti-Dfaex7 anti-
body (by confirming that the antibody-recognized 35-kDa pro-
tein was indeed encoded byDfa in 3T3 cells) and also suggested
that DfaA may be required for viability of mammalian cells.
Dfa Interactions with GgnBP1 and Abt1—To search for
DfaA-binding proteins, we employed the yeast two-hybrid
assay, with a Gal4-DNA-binding-DfaA fusion as a bait and a
mouse testis cDNA library based on the Gal4-activation
domain.We isolated 16 independent DNA clones that encoded
different (overlapping) segments of the mouse gametogenesis
binding protein-1 (50, 51) (GgnBP1; GenBankTM accession
number Q6K1E7) from 32 yeast colonies (Fig. 5A). Sequence
analyses of the 16 pACT2-based encoding segments of GgnBP1
mapped the DfaA-binding region of GgnBP1 to its C-terminal
residues 262–370 that encompass the C-terminal DUF1055
domain (domain of unknown function) that is present in many
mammalian deubiquitylating enzymes (Fig. 5A). To further ver-
ify the GgnBP1-DfaA interaction and to examine the ability of
GgnBP1 to interact with DfaB, we coexpressed Gal4-DNA-
binding domain (DBD) fusions (DfaA, DfaB, Ate1, GgnBP(53–
370), GgnBP1(262–370), and p53 (the latter a control)) with
Gal4 activation domain fusions (DfaA, DfaB, GgnBP(53–370),
and GgnBP1(262–370)), and the SV40 large T antigen (the lat-
ter as a control) in appropriately marked S. cerevisiae strains
(Fig. 5C). These strains were assayed for their ability grow on
SD media lacking Leu, Trp, His, and Ade (QDO, Quadrupole
DropOut) as the evidence for interaction of the corresponding
fusions (Fig. 5C). These assays confirmed, in the framework of
two-hybrid assays, that either DfaA or DfaB interacted with
GgnBP1(53–370) (residues 53–370, the largest GgnBP1 frag-
ment isolated in this screen) or GgnBP1(262–370) (residues
262–370 of GgnBP1; the smallest “positive” GgnBP1 fragment)
(Fig. 5C). “Vector swapping” two-hybrid assays further vali-
dated these Dfa-GgnBP1 interactions (Fig. 5C). In sum, the
C-terminal DUF1055 domain of GgnBP1, which included
GgnBP1(262–370), was sufficient for an interaction of GgnBP1
with either DfaA or DfaB (Fig. 5C).
GgnBP1 was originally identified in two-hybrid analyses as a
protein that interacted with Ggn1 (gametogenetin 1) (50, 51).
Ggn1 is a germ cell-specific protein that binds to FANCL (Fan-
coni anemia complementation group L), the protein product of
the gene mutated in gcd (germ cell-deficient) mice (52, 53).
GgnBP1 is associatedwith theGolgi and the plasmamembrane,
is testis-specific, and is expressed primarily in meiotic sper-
matocytes (51). More recently, mouse GgnBP1 was found,
using a two-hybrid assay, to interact with the mitochondrial
fission factor FIS1 and to participate, through the DUF1055
domain of GgnBP1, in the mitochondrial morphogenesis dur-
ing spermatogenesis (54).
Although all of the above GgnBP1-interacting partners have
been robustly identified through yeast two-hybrid assays, none
of these interactions could be verified, so far, by other means,
e.g. through coimmunoprecipitation of proteins expressed in
mammalian cells (50–54). For reasons unknown (possibly
because Dfa exists in multiple, differently located intracellular
pools), our attempts to coimmunoprecipitate GgnBP1withDfa
in mammalian cells were also unsuccessful (data not shown).
Given specific membrane locations of GgnBP1 (see above), and
the association of DfaA with both nuclear and membrane frac-
tions (Fig. 3, D, G, and J), a subset of DfaJ that interacts with
GgnBP1 is likely to be a small one. Recombinant mouse DfaA,
when expressed alone in E. coli, was detected in both soluble
and insoluble fractions after cell lysis, whereas all DfaA became
insoluble when it was coexpressed with recombinant mouse
Ggnbp1 (Fig. 5B), a finding in agreement with extensive two-
hybrid data for a DfaA-Ggnbp1 interaction (Fig. 5).
Two-hybrid assayswithDfaA as a bait also yielded three inde-
pendent cDNA clones encoding overlapping segments of the
mouse Abt1 (activator of basal transcription) protein. In addi-
tional two-hybrid screens, we found that, similarly to the
GgnBP1 protein, Abt1 could interact with both the DfaA and
DfaB isoforms (Fig. 6A). To verify and extend these findings,
NIH-3T3 cells were transiently cotransfected with plasmids
that expressed triple FLAG-tagged f3DfaA and tripleHA-tagged
h3Abt1 (Fig. 6B). In agreement with the results of two-hybrid
assays (Fig. 6A), h3Abt1 was specifically coimmunoprecipitated
with f3DfaA, using anti-FLAG-M2 beads (Fig. 6B). Thus, DfaA
andAbt1can interact inbothS. cerevisiaeandmouse fibroblasts. It
should also be noted that no interaction between DfaA and Ate1
(R-transferase; see Introduction) was detected using two-hybrid
assay (data not shown), in agreement with other evidence in this
study that suggested the absence of a significant functional or
mechanistic connection between Dfa and Ate1, apart from their
proximity and head-to-tail orientation (Fig. 1A).
Dfa Acts As a Transcriptional Repressor of a TATA-box
Promoter—Previous work has shown that Abt1 is associated
with the TATA-box-binding protein and enhances transcrip-
tional activity of TATA-containing promoters (55). As de-
scribed above, Dfa was shown to interact with Abt1 both in
yeast-based two-hybrid assays and in coimmunoprecipitation
assays with mammalian cells (Fig. 6, A and B), and it was also
found to be associated in vivo with condensed nuclear IGCs, a
hallmark of transcriptional repression (Fig. 3, L–Q). To deter-
mine whether DfaA could influence the in vivo transcription of
a reporter gene, we transiently cotransfected NIH-3T3 cells
with a plasmid that expressed luciferase from the TATA-con-
taining PCMV promoter, and with increasing amounts of the
DfaA-expressing pCB180plasmid (Fig. 6D). (To control for pro-
moter titration effects, transfection samples were normalized
by the addition of the pcDNA3.1 vector DNA.) Addition of
increasing amounts of the DfaA-expressing plasmid progres-
sively decreased the expression of luciferase (Fig. 6D), suggest-
ing that DfaA acted as a transcriptional repressor, possibly
through its interaction with endogenous Abt1. To verify that
the transcriptional repression observed under these conditions
was caused by DfaA, we repeated these assays in the presence of
DFash4 (see above) and the resulting RNAi-mediated down-
regulation of DfaA. In the absence of DfaA-specific RNAi, the
addition of 2g of theDfaA-expressing pCB180 plasmid caused
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FIGURE 5. Two-hybrid assay detects interaction of DfaA with Ggnbp1. A, diagram of different segments of the mouse GgnBP1 protein that were
isolated in 16 independent “two-hybrid-positive” clones from32 separate S. cerevisiae colonies. The number of times each segment GgnBP1was isolated
in two-hybrid assays is shown in parentheses to the right. The DUF1055 domain of GgnBP1 (between residues 300 and 358) is shaded. B, soluble (upper
two panels) and insoluble (solubilized by guanidine-HCl) proteins from BL21 (DE3) E. coli cells that had been transformed with pET-Duet1 plasmids (see
“Experimental Procedures”). Lane 1, E. coli expressingmouse His6-Dfa
A. Lane 2, E. coli expressing N-terminally HA-taggedmouse haGgnBP1. Lane 3, E. coli
expressing both His6-Dfa
A and haGgnBP1. Note a decrease in the fraction of soluble His6-Dfa
A in the presence of coexpressed (and virtually entirely
insoluble) haGgnBP1 (cf. lanes 1 and 3). C, indicated DBD fusion and activation domain (AD) fusion proteins were expressed in S. cerevisiae YH109 and
assayed for their ability to grow on SD medium lacking either Leu and Trp or lacking Leu, Trp, His, and Ade (QDO (Quadruple DropOut) media; see the
main text and see under “Experimental Procedures”).
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an 42% reduction in luciferase levels, in comparison with
expression in the presence of the DfaA-lacking pcDNA3.1 vec-
tor (Fig. 6D). In contrast, the DfaA-specific RNAi (verified,
using immunoblotting, by a loss of DfaA expression upon
RNAi) and the resulting down-regulation of DfaA increased
luciferase expression to 70% of the control levels (in the
absence of exogenous DfaA) (Fig. 6D). In additional control
experiments, no effect on DfaA expression or its reporter-re-
pressive effects were observed with cells that were also trans-
fectedwith the “control” RNAi plasmid pEN-hU6miR (Fig. 6D).
Given these results, we also asked whether DfaA could also
repress transcription from the bidirectional and TATA-less
PAte1/Dfa promoter, as such a property would potentially be a
functional link between Ate1 and Dfa. We measured the levels
of luciferase expressed (in the direction of Ate1 transcription)
from the PAte1/Dfa promoter under the conditions described
above for the PCMV-luciferase setting. In contrast to down-reg-
ulating effects of DfaA on the expression of PCMV-luciferase,
increasing levels of DfaA did not alter significantly the expres-
sion of the PAte1/Dfa-luciferase reporter (Fig. 6C). Although
FIGURE6.DfaA interactswithAbt1andinhibits transcriptionfromtheTATA-containingPCMVpromoter.A, indicatedAbt1-basedandDfa-basedDBDfusionand
activation domain (AD) fusion proteins were expressed in S. cerevisiae YH109, and two-hybrid assays for their interaction were carried out (see under “Experimental
Procedures”). QDO, quadruple dropout. B, mouse NIH-3T3 cells were transiently transfected with pcDNA-based plasmids that expressed the indicated proteins
(tagged with the FLAG or HA epitopes), followed by preparation of extracts, and either SDS-PAGE (followed by immunoblotting with anti-FLAG and anti-HA) or
immunoprecipitation with anti-FLAG antibody, followed by SDS-PAGE of immunoprecipitates and immunoblotting with anti-HA antibody. IB, immunoblotting; IP,
immunoprecipitation. C, levels of luciferase (expressed from the PAte1/Dfa promoter in the plasmid pCB44 (14)) in extracts frommouse NIH-3T3 cells that had been
cotransfected with pCB44 and the indicated plasmids (the empty vector pCDNA; the f3DfaA-expressing pCB180, and the DFAsh4 shRNA-expressing pEN-DFAsh4).
Luciferase levels are plotted as percentages of the level that was observed with pcDNA3.1 vector alone (no exogenous DfaA; no DFAsh4 shRNA). Error bars indicate
standarddeviations among three independent assays.D, same as inCbutwith luciferase expressed from the TATA-box-containing PCMVpromoter. The immunoblot
inD shows relative levels of f3DfaA in the corresponding cotransfected cells. An asterisk denotes a protein cross-reactingwith anti-FLAG antibody.
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more detailed studies of Dfa as a transcriptional repressor of
TATA-containing promoters are clearly necessary, our find-
ings suggest that the repressor activity of DfaA is confined to
promoters of this class.
Concluding Remarks—This study of the previously unchar-
acterized mouse gene, termed Dfa, was carried out to explore
the possibility that both proximity and head-to-head orienta-
tion of the Dfa gene and the previously known Ate1 gene
(encoding R-transferase of the N-end rule pathway) might sig-
nify their functional link, either directly or through belonging
to a specific regulatory circuit. As shown in this work, Dfa is
expressed largely, although not exclusively, in the testis, where
it produces a complex set of splicedDfamRNAs from both the
bidirectional PAte1/Dfa promoter and other nearby promoters.
The 3-terminal exon of Dfa, termed DfaA and shared by other
mapped Dfa mRNAs, encodes a 217-residue (26 kDa) protein
that was found to migrate, upon SDS-PAGE, as a 35-kDa spe-
cies. An affinity-purified polyclonal antibody to DfaA was pre-
pared and shown to recognize DfaA in cell extracts. Specifically,
the antibody detected a 35-kDa protein that was down-regu-
lated uponRNAi-mediated repression ofDfa. TheDfaA protein
was sequelogous (similar in sequence) (18) to the previously
described human/mouse HTEX4 protein, whose physiological
function is unknown. DfaA was also found to interact with spe-
cific proteins, including theAbt1 transcriptional activator. Dfa-
Abt1 interactions could be detected either by the yeast-based
two-hybrid assay or through coimmunoprecipitation of the two
proteins from mammalian cell extracts. This potential link
between DfaA and regulation of transcription was consistent
with the observed preferential location of DfaA (as an EGFP-
DfaA fusion) in compact (condensed) interchromatin granule
clusters, a hallmark of transcriptional repression. Experiments
with a luciferase-based transcriptional reporter and DfaA-spe-
cific RNAi have shown that DfaA acts as a repressor of a TATA-
box-containing transcriptional promoter but does not influ-
ence the bidirectional PAte1/Dfa promoter, which contains a
CpG island and lacks the TATA-box.
Much remains to be learned about Dfa, its elaborate set of
primary transcripts, differential splicing, mature mRNAs, the
observed transcriptional-repressor activity of Dfa, and ulti-
mately its specific roles in cell physiology. Contrary to expecta-
tion that led us to initiate this work, no functional ormechanis-
tic connections between Dfa proteins and the isoforms of the
Ate1 R-transferase were detected so far, apart from the prox-
imity of their head-to-head oriented genes and the antisense
orientation of some among Dfa and Ate1 transcripts (Fig. 1, A
and D). As this is the first exploration of Dfa and is also a far
from complete understanding of the PAte1/Dfa promoter, future
studies of Dfa and Ate1may still uncover a physiologically rel-
evant connection between these adjacent, divergently oriented
genes, perhaps outside of domains we explored so far.
Acknowledgments—We are grateful to current and former members
of the Varshavsky laboratory for advice and help. We thank K. I.
Piatkov for helpful discussions, J. Zavzavadjian andE.Wall for advice
with shRNA, and E. Udartseva for excellent technical assistance.
REFERENCES
1. Varshavsky, A. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 12142–12149
2. Mogk, A., Schmidt, R., and Bukau, B. (2007) Trends Cell Biol. 17, 165–172
3. Tasaki, T., and Kwon, Y. T. (2007) Trends Biochem. Sci. 32, 520–528
4. Varshavsky, A. (2008) Nat. Struct. Mol. Biol. 15, 1238–1240
5. Varshavsky, A. (2008) J. Biol. Chem. 283, 34469–34489
6. Hu, R. G., Sheng, J., Qi, X., Xu, Z., Takahashi, T. T., and Varshavsky, A.
(2005) Nature 437, 981–986
7. Hu, R. G., Wang, H., Xia, Z., and Varshavsky, A. (2008) Proc. Natl. Acad.
Sci. U.S.A. 105, 76–81
8. Xia, Z., Webster, A., Du, F., Piatkov, K., Ghislain, M., and Varshavsky, A.
(2008) J. Biol. Chem. 283, 24011–24028
9. Hwang, C. S., and Varshavsky, A. (2008) Proc. Natl. Acad. Sci. U.S.A. 105,
19188–19193
10. Hwang, C. S., Shemorry, A., and Varshavsky, A. (2009) Proc. Natl. Acad.
Sci. U.S.A. 106, 2142–2147
11. Wang, H., Piatkov, K. I., Brower, C. S., and Varshavsky, A. (2009)Mol. Cell
34, 686–695
12. Brower, C. S., and Varshavsky, A. (2009) PLoS ONE 4, e7757
13. Hwang, C. S., Shemorry, A., and Varshavsky, A. (2010) Science 327,
973–977
14. Hu, R.G., Brower, C. S.,Wang,H., Davydov, I. V., Sheng, J., Zhou, J., Kwon,
Y. T., and Varshavsky, A. (2006) J. Biol. Chem. 281, 32559–32573
15. Kwon, Y. T., Kashina, A. S., and Varshavsky, A. (1999)Mol. Cell. Biol. 19,
182–193
16. Kwon, Y. T., Kashina, A. S., Davydov, I. V., Hu, R. G., An, J. Y., Seo, J. W.,
Du, F., and Varshavsky, A. (2002) Science 297, 96–99
17. Lee, M. J., Tasaki, T., Moroi, K., An, J. Y., Kimura, S., Davydov, I. V., and
Kwon, Y. T. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 15030–15035
18. Varshavsky, A. (2004) Curr. Biol. 14, R181–R183
19. Graciet, E., Hu, R. G., Piatkov, K., Rhee, J. H., Schwarz, E. M., and Var-
shavsky, A. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 3078–3083
20. Shin, K. J., Wall, E. A., Zavzavadjian, J. R., Santat, L. A., Liu, J., Hwang, J. I.,
Rebres, R., Roach, T., Seaman, W., Simon, M. I., and Fraser, I. D. (2006)
Proc. Natl. Acad. Sci. U.S.A. 103, 13759–13764
21. Prioleau, M. N. (2009) PLoS Genetics 5, e1000454
22. Patton, J., Block, S., Coombs, C., and Martin, M. E. (2006) Gene 369,
35–44
23. Emoto, M., Miki, M., Sarker, A. H., Nakamura, T., Seki, Y., Seki, S., and
Ikeda, S. (2005) Gene 357, 47–54
24. Travers, M. T., Cambot, M., Kennedy, H. T., Lenoir, G. M., Barber, M. C.,
and Joulin, V. (2005) Genomics 85, 71–84
25. Saleh, A., Davies, G. E., Pascal, V., Wright, P. W., Hodge, D. L., Cho, E. H.,
Lockett, S. J., Abshari,M., andAnderson, S. K. (2004) Immunity 21, 55–66
26. Meier-Noorden, M., Flindt, S., Kalinke, U., and Hinz, T. (2004)Gene 338,
197–207
27. Whitehouse, C., Chambers, J., Catteau, A., and Solomon, E. (2004) Gene
326, 87–96
28. Trinklein, N. D., Aldred, S. F., Hartman, S. J., Schroeder, D. I., Otillar, R. P.,
and Myers, R. M. (2004) Genome Res. 14, 62–66
29. Takai, D., and Jones, P. A. (2004)Mol. Biol. Evol. 21, 463–467
30. Adachi, N., and Lieber, M. R. (2002) Cell 109, 807–809
31. West, A. B., Lockhart, P. J., O’Farell, C., and Farrer,M. J. (2003) J.Mol. Biol.
326, 11–19
32. Li, Y. Y., Yu, H., Guo, Z. M., Guo, T. Q., Tu, K., and Li, Y. X. (2006) PLoS
Comp. Biol. 2, e74
33. Seila, A. C., Calabrese, J. M., Levine, S. S., Yeo, G. W., Rahl, P. B., Flynn,
R. A., Young, R. A., and Sharp, P. A. (2008) Science 322, 1849–1851
34. He, Y., Vogelstein, B., Velculescu, V. E., Papadopoulos, N., and Kinzler,
K. W. (2008) Science 322, 1855–1857
35. Piontkivska, H., Yang, M. Q., Larkin, D. M., Lewin, H. A., Reecy, J., and
Elnitski, L. (2009) BMC Genomics 10, 189
36. Xu, Z.,Wei,W., Gagneur, J., Perocchi, F., Clauder-Mu¨nster, S., Camblong,
J., Guffanti, E., Stutz, F., Huber, W., and Steinmetz, L. M. (2009) Nature
457, 1033–1037
37. Teodorovic, S., Walls, C. D., and Elmendorf, H. G. (2007) Nucleic Acids
Res. 35, 2544–2553
Dfa Protein
MAY 28, 2010•VOLUME 285•NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 17233
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y, on June 11, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
38. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Smith, J. A.,
Seidman, J. G., and Struhl, K. (eds) (2006) Current Protocols in Molecular
Biology, Wiley-Interscience, New York
39. Chen, M., and Manley, J. L. (2009) Nat. Rev. Mol. Cell Biol. 10, 741–754
40. Elnitski, L., Riemer, C., Burhans, R., Hardison, R., and Miller, W. (2005)
Curr. Protoc. Bioinformatics, Unit 10.14
41. Elnitski, L., Riemer, C., Schwartz, S., Hardison, R., and Miller, W. (2003)
Curr. Protoc. Bioinformatics, Unit 10.12
42. Scherf, M., Klingenhoff, A., and Werner, T. (2000) J. Mol. Biol. 297,
599–606
43. Coriton,O., Lepourcelet,M.,Hampe,A.,Galibert, F., andMosser, J. (2000)
Mamm. Genome 11, 1127–1131
44. Lepourcelet,M., Coriton,O.,Hampe,A.,Galibert, F., andMosser, J. (1998)
Immunogenetics 47, 491–496
45. Seibel, N.M., Eljouni, J., Nalaskowski,M.M., andHampe,W. (2007)Anal.
Biochem. 368, 95–99
46. Saitoh, N., Spahr, C. S., Patterson, S. D., Bubulya, P., Neuwald, A. F., and
Spector, D. L. (2004)Mol. Biol. Cell 15, 3876–3890
47. Bregman, D. B., Du, L., van der Zee, S., andWarren, S. L. (1995) J. Cell Biol.
129, 287–298
48. Lamond, A. I., and Spector, D. L. (2003) Nat. Rev. Mol. Cell Biol. 4,
605–612
49. Wang, I. F., Chang, H. Y., and Shen, C. K. (2006) Exp. Cell Res. 312,
3796–3807
50. Zhang, J., Wang, Y., Zhou, Y., Cao, Z., Huang, P., and Lu, B. (2005) FEBS
Lett. 579, 559–566
51. Zhou, Y., Zhao, Q., Bishop, C. E., Huang, P., and Lu, B. (2005)Mol. Reprod.
Dev. 70, 301–307
52. Lu, B., and Bishop, C. E. (2003) J. Biol. Chem. 278, 16289–16296
53. Agoulnik, A. I., Lu, B., Zhu, Q., Truong, C., Ty, M. T., Arango, N., Chada,
K. K., and Bishop, C. E. (2002) Hum. Mol. Genet. 11, 3047–3053
54. Aihara, T., Nakamura, N., Honda, S., and Hirose, S. (2009) Biol. Reprod.
80, 762–770
55. Oda, T., Kayukawa, K., Hagiwara, H., Yudate, H. T., Masuho, Y., Mu-
rakami, Y., Tamura, T. A., and Muramatsu, M. A. (2000) Mol. Cell. Biol.
20, 1407–1418
Dfa Protein
17234 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 22•MAY 28, 2010
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y, on June 11, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
